NEWS

February 3, 2022

Healthcare Royalty Partners Details HCR’s Record For Royalty Receipts and Market Activity in 2021 Year In Review

September 30, 2021

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners^® for Up to $125 Million

August 26, 2021

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

June 24, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

May 5, 2021

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases

March 31, 2021

Aptevo Therapeutics Announces Sale of Ruxience Royalty Payments to HCR

March 29, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

February 25, 2021

Akebia Announces $60 Million Transaction with HealthCare Royalty

January 6, 2021

HCR Expands Team and Announces Promotions

December 22, 2020

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma^® Royalties for $200 Million